16 September 2025
Medicine shortages are increasingly affecting patients and clinicians across rheumatology. Among the most concerning are the recent disruptions to Triamcinolone hexacetonide and Triamcinolone acetonide, two key medicines used for intra-articular injections in children with juvenile idiopathic arthritis (JIA). These shortages have created significant challenges for paediatric rheumatology teams, patients, and their families.
To support the community, the British Society for Rheumatology (BSR) has produced a new briefing that outlines the situation and provides guidance on navigating care during this difficult period.
It then shares findings from a UK-wide survey of rheumatology centres and highlights the key clinical considerations when choosing alternatives, such as efficacy, duration of action, safety, and cost.
By gathering insights, setting out practical recommendations, and continuing to work with government and regulators, BSR aims to support clinical teams in ensuring children with JIA continue to receive safe and effective treatment despite ongoing shortages.